Peptide Synthesis Market worth $1.41 billion in 2029
The report "Peptide Synthesis Market by Reagents (Resins, Amino Acid, Dyes), Instruments (Peptide Synthesizer, Chromatography, Lyophilizer), Technique (Solid-phase, Solution-phase, Hybrid), Services, Application (Therapeutics), End User - Global Forecast to 2029", is estimated to expand to a value of USD 1.41 billion in 2029 from USD 0.81 billion in 2024, growing at a CAGR of 11.7%. The rise in biopharmaceutical research and the use of synthetic peptides in vaccine development, such as mRNA vaccines, is likely to fuel market growth. The outsourcing trend for peptide synthesis services by pharmaceutical companies to reduce costs and focus on core competencies is further likely to support market expansion. Technological advancements in the instruments and launch of new products in the market is further likely to drive the market growth at faster pace.
Browse 900 market data Tables and 53 Figures spread through 563 Pages and in-depth TOC on "Peptide Synthesis Market by Reagents (Resins, Amino Acid, Dyes), Instruments (Peptide Synthesizer, Chromatography, Lyophilizer), Technique (Solid-phase, Solution-phase, Hybrid), Services, Application (Therapeutics), End User - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/peptide-synthesis-market-158927365.html
The products segment accounted for the largest share of the offerings segment in the peptide synthesis market in 2023.
Based on offerings, the market is segmented into products and services. By-products market is further divided into consumables and instruments. Among these consumables dominated the peptide synthesis market. The consumables segment is further bifurcated into reagents and other consumables. The reagents market is further divided into resins, amino acids, coupling reagents, dyes & fluorescent labeling reagents, deprotection agents, cleavage reagents, and other reagents. The instruments segment is further divided into peptide synthesizers, chromatography equipment, lyophilizers, and others. The peptide synthesizer segment is further divided into automated and manual peptide synthesizers. Technological advancements in the peptide synthesizer and the launch of new products in the market are likely to uplift the segmental growth. In May 2024, Activotec Ltd, launched Activo-Darwin Semi-Automated Peptide Synthesizer, a instrument designed for the synthesis of very high quality peptides.
Peptide synthesis services is anticipated to grow at significant CAGR during the forecast period.
The services segment is further divided into peptide library synthesis, peptide synthesis, peptide purification services, and peptide analysis services. The peptide synthesis segment dominated the services segment. Leading companies such as Bachem, GenScript, and Thermo Fisher Scientific provide a wide range of peptide synthesis services, including custom synthesis, peptide modifications, and large-scale production. The increasing complexity of peptides, with long chains and non-standard amino acids propelled the need of peptide synthesis services contributing towards segmental growth.
Solid-Phase Peptide Synthesis (SPPS) dominated the technique segment in 2023.
Based on technique, the peptide synthesis market is segmented into chemical and biological. The chemical segment is further divided into solid-phase peptide synthesis, solution-phase peptide synthesis, and others. The biological segment is divided into recombinant DNA technology and enzymes. The solid-phase peptide synthesis (SPPS) segment leads the peptide synthesis market, driven by its efficiency, scalability, and extensive use in both research and commercial settings. SPPS facilitates the sequential assembly of peptides on an insoluble resin, enabling fast synthesis and simplified purification.
Cancer segment dominated the technique segment in 2023.
Based on application, the market is divided into therapeutics, diagnostics, and research & development. Therapeutics by indication is further divided into cancer, diabetes, obesity, autoimmune disease, and other disease indications. Therapeutics by molecules is further segmented into peptide-based vaccines, peptide-drug conjugates (PDCs), peptide inhibitors, and other molecules. The cancer segment dominated the therapeutics by indication segment and is anticipated to grow at a significant CAGR during the forecast period. Factors attributable to the growth is growing demand for peptide-based cancer therapies and diagnostics and rise of immunotherapy has further fueled the adoption of peptides in cancer treatment.
Pharmaceutical and Biotechnology companies segment lead the end users segment in 2023.
The peptide synthesis market is segmented by end users into pharmaceutical and biotechnology companies, CDMOS & CROS, academic and research institutes, medical device companies, and hospitals and diagnostic centers. Increased investment in the novel peptide-based therapies and diagnostics is rising demand for peptide synthesis by pharmaceutical and biotechnology companies is one of the major contributing to the dominance of the segment.
North America region dominated the Peptide Synthesis market.
The Peptide Synthesis market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the region segment owing to the adoption of advanced technologies, increased investment in the peptide-based therapeutics and presence of leading companies in the region. Asia Pacific region anticipated The Asia-Pacific (APAC) region is witnessing rapid growth in the peptide synthesis market, driven by increasing healthcare investments, expanding pharmaceutical and biotechnology industries, and rising demand for peptide-based therapeutics.
The prominent players operating in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Kaneka Corporation (Japan), GenScript Biotech Corporation (China), and Bachem Holding AG (Switzerland), among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Peptide Synthesis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
